Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00460811
First received: April 13, 2007
Last updated: January 29, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.


Condition Intervention Phase
Irritable Bowel Syndrome With Constipation
Drug: Linaclotide Acetate
Drug: Matching placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-design, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Irritable Bowel Syndrome With Constipation

Resource links provided by NLM:


Further study details as provided by Ironwood Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period.

    The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.



Secondary Outcome Measures:
  • CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate) [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.

  • Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    SBMs were measured daily during the treatment period by patient calls to the IVRS.

  • Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).

  • Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.

  • Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).

  • Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe


Enrollment: 420
Study Start Date: April 2007
Study Completion Date: April 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 72 ug linaclotide acetate Drug: Linaclotide Acetate
Oral, once daily
Active Comparator: 145 ug linaclotide acetate Drug: Linaclotide Acetate
Oral, once daily
Active Comparator: 290 ug linaclotide acetate Drug: Linaclotide Acetate
Oral, once daily
Active Comparator: 579 ug linaclotide acetate Drug: Linaclotide Acetate
Oral, once daily
Placebo Comparator: Matching Placebo Drug: Matching placebo
Oral, once daily

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must not be pregnant or breastfeeding and agree to use birth control;
  • Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings;
  • Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria;
  • Demonstrates English fluency and has access to a touch-tone telephone.

Exclusion Criteria:

  • Recent history of mushy or watery stools;
  • Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study;
  • Clinically-significant alarm symptoms;
  • Secondary causes of constipation or evacuation disorders;
  • Surgery to the gastrointestinal tract;
  • Usage of prohibited medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460811

  Hide Study Locations
Locations
United States, Alabama
Microbia Investigational Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Microbia Investigational Site
Chandler, Arizona, United States
Microbia Investigational Site
Tuscon, Arizona, United States
United States, Arkansas
Microbia Investigational Site
Sherwood, Arkansas, United States
United States, California
Microbia Investigational Site
Anaheim, California, United States
Microbia Investigational Site
Garden Grove, California, United States
Microbia Investigational Site
Sacramento, California, United States
Microbia Investigational Site
San Diego, California, United States
United States, Connecticut
Microbia Investigational Site
Bristol, Connecticut, United States
United States, Florida
Microbia Investigational Site
Boynton Beach, Florida, United States
Microbia Investigational Site
Dunedin, Florida, United States
Microbia Investigational Site
Largo, Florida, United States
Microbia Investigational Site
Ocala, Florida, United States
Microbia Investigational Site
Port Orange, Florida, United States
Microbia Investigational Site
Stuart, Florida, United States
Microbia Investigational Site
Tampa, Florida, United States, 33607
United States, Georgia
Microbia Investigational Site
Stockbridge, Georgia, United States
United States, Illinois
Microbia Investigational Site
Libertyville, Illinois, United States
Microbia Investigational Site
Peoria, Illinois, United States, 60601
United States, Iowa
Microbia Investigational Site
Clive, Iowa, United States
Microbia Investigational Site
Davenport, Iowa, United States
United States, Kansas
Microbia Investigational Site
Mission, Kansas, United States
Microbia Investigational Site
Shawnee, Kansas, United States
United States, Louisiana
Microbia Investigational Site
Baton Rouge, Louisiana, United States
Microbia Investigational Site
Monroe, Louisiana, United States, 71201
Microbia Investigational Site
West Monroe, Louisiana, United States
United States, Maryland
Microbia Investigational Site
Annapolis, Maryland, United States
Microbia Investigational Site
Silver Spring, Maryland, United States
United States, Massachusetts
Microbia Investigational Site
Fall River, Massachusetts, United States
United States, Michigan
Microbia Investigational Site
Ann Arbor, Michigan, United States
United States, Missouri
Microbia Investigational Site
St. Louis, Missouri, United States
United States, Montana
Microbia Investigational Site
Missoula, Montana, United States
United States, Nevada
Microbia Investigational Site
Henderson, Nevada, United States
Microbia Investigational Site
Las Vegas, Nevada, United States
United States, New Jersey
Microbia Investigational Site
Blackwood, New Jersey, United States
United States, New York
Microbia Investigational Site
Great Neck, New York, United States, 11020
Microbia Investigational Site
Pittsford, New York, United States
United States, North Carolina
Microbia Investigational Site
Asheville, North Carolina, United States
Microbia Investigational Site
Chapel Hill, North Carolina, United States
Microbia Investigational Site
Elkin, North Carolina, United States
Microbia Investigational Site
Greensboro, North Carolina, United States
Microbia Investigational Site
Harrisburg, North Carolina, United States
Microbia Investigational Site
Hickory, North Carolina, United States
Microbia Investigational Site
Raleigh, North Carolina, United States
Microbia Investigational Site
Statesville, North Carolina, United States
Microbia Investigational Site
Winston-Salem, North Carolina, United States
United States, Ohio
Microbia Investigational Site
Cincinnati, Ohio, United States
Microbia Investigational Site
Cleveland, Ohio, United States
Microbia Investigational Site
Dayton, Ohio, United States
Microbia Investigational Site
Sylvania, Ohio, United States
United States, Oklahoma
Microbia Investigational Site
Oklahoma City, Oklahoma, United States
Microbia Investigational Site
Tulsa, Oklahoma, United States
Microbia Investigational Site
Yukon, Oklahoma, United States
United States, Oregon
Microbia Investigational Site
Medford, Oregon, United States
United States, Pennsylvania
Microbia Investigational Site
Levittown, Pennsylvania, United States
Microbia Investigational Site
Pittsburgh, Pennsylvania, United States
Microbia Investigational Site
Reading, Pennsylvania, United States
Microbia Investigational Site
Sellersville, Pennsylvania, United States, 18960
United States, South Carolina
Microbia Investigational Site
Anderson, South Carolina, United States
Microbia Investigational Site
Mt. Pleasant, South Carolina, United States
Microbia Investigational Site
Simpsonville, South Carolina, United States
Microbia Investigational Site
Summerville, South Carolina, United States
United States, Tennessee
Microbia Investigational Site
Bristol, Tennessee, United States
Microbia Investigational Site
Germantown, Tennessee, United States
Microbia Investigational Site
Jackson, Tennessee, United States
Microbia Investigational Site
Kingsport, Tennessee, United States
United States, Texas
Microbia Investigational Site
Beaumont, Texas, United States
Microbia Investigational Site
Corsicana, Texas, United States
Microbia Investigational Site
El Paso, Texas, United States
Microbia Investigational Site
San Antonio, Texas, United States
United States, Utah
Microbia Investigational Site
Ogden, Utah, United States
United States, Virginia
Microbia Investigational Site
Chesapeake, Virginia, United States
Microbia Investigational Site
Lynchburg, Virginia, United States
Microbia Investigational Site
Richmond, Virginia, United States
United States, Washington
Microbia Investigational Site
Lakewood, Washington, United States
Microbia Investigational Site
Olympia, Washington, United States
Microbia Investigational Site
Vancouver, Washington, United States
United States, West Virginia
Microbia Investigational Site
Charleston, West Virginia, United States
United States, Wisconsin
Microbia Investigational Site
LaCrosse, Wisconsin, United States
Canada, British Columbia
Microbia Investigational Site
Abbortsford, British Columbia, Canada
Canada, Manitoba
Microbia Investigational Site
Winnipeg, Manitoba, Canada
Canada, Ontario
Microbia Investigational Site
Guelph, Ontario, Canada
Microbia Investigational Site
Milton, Ontario, Canada
Microbia Investigational Site
Toronto, Ontario, Canada
Canada, Saskatchewan
Microbia Investigational Site
Saskatoon, Saskatchewan, Canada
Sponsors and Collaborators
Ironwood Pharmaceuticals, Inc.
Investigators
Study Director: Microbia Medical Director, MD Microbia, Inc.
  More Information

No publications provided by Ironwood Pharmaceuticals, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00460811     History of Changes
Other Study ID Numbers: MCP-103-202
Study First Received: April 13, 2007
Results First Received: September 28, 2012
Last Updated: January 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Ironwood Pharmaceuticals, Inc.:
Irritable Bowel Syndrome with Constipation
IBS
Irritable Bowel Syndrome
linaclotide acetate
linaclotide
MD-1100

Additional relevant MeSH terms:
Constipation
Irritable Bowel Syndrome
Syndrome
Colonic Diseases
Colonic Diseases, Functional
Digestive System Diseases
Disease
Gastrointestinal Diseases
Intestinal Diseases
Pathologic Processes
Signs and Symptoms
Signs and Symptoms, Digestive

ClinicalTrials.gov processed this record on October 20, 2014